Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13601341 | 0.82 | HPGD (0.60) | ALDH1A1SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL13117610 | 0.81 | TACR3 (0.52) | HPGD | |
| SCHEMBL13601210 | 0.81 | HPGD (0.59) | ALDH1A1MEN1KMT2APOLBHPGD | |
| SCHEMBL13601310 | 0.81 | MEN1 (0.57) | ALDH1A1MEN1KMT2APOLBHPGD | |
| SCHEMBL25229665 | 0.81 | ALDH1A1 (0.72) | ALDH1A1HSD17B10SMN1; SMN2LMNAMEN1 | |
| SCHEMBL30466121 | 0.81 | ALDH1A1 (0.72) | ALDH1A1HSD17B10SMN1; SMN2LMNAMEN1 | |
| SCHEMBL13601352 | 0.79 | MEN1 (0.55) | ALDH1A1SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL13117439 | 0.79 | HPGD (0.58) | ALDH1A1SMN1; SMN2LMNAHTTHPGD | |
| SCHEMBL4319182 | 0.78 | ALDH1A1 (0.62) | ALDH1A1HSD17B10SMN1; SMN2LMNAMEN1 | |
| SCHEMBL4323101 | 0.78 | ALDH1A1 (0.75) | ALDH1A1MEN1KMT2APOLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | ALDH1A1 3104/4885HSD17B10 3322/4885SMN1; SMN2 3956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.